ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

aprocitentan

Also written as “Aprocitentan”, “Aprocitentan 25 mg” and “Aprocitentan tablets(SYH9108)”.

Its studies are mostly in Hypertension · Liver Diseases · Essential Hypertension · Renal Insufficiency, led by 2 companies.

Drug pageAprocitentan: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 17, 201814 company-led studies, 1 open or runningNext primary completion: Dec 28, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Idorsia Pharmaceuticals130 open or runningphase 3since May 17, 2018Nov 9, 2015none ahead
CSPC Pharmaceutical Groupits history only11 open or runningphase 3since May 29, 2026May 29, 2026Dec 28, 2029phase 3 · NCT07635914

Also a collaborator on its studies: Johnson & Johnson.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Idorsia Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2015First study: phase 2 study in Essential HypertensionFirst studyNCT02603809 · 1,659 enrolled · United States, Canada, Israel and more
  2. Feb 24, 2016Phase 1 study in Healthy SubjectsNCT02708004 · 24 enrolled · Switzerland
  3. Jul 20, 2016Phase 1 study in Healthy SubjectsNCT02841761 · 20 enrolled · United States
  4. Dec 9, 2016Named aprocitentanINNProposed as its International Nonproprietary Name in WHO's List 116
  5. Mar 29, 2017Phase 1 study in Healthy SubjectsNCT03100591 · 6 enrolled · Netherlands
  6. May 23, 2017Phase 1 study in Renal InsufficiencyNCT03165071 · 16 enrolled · Czechia
  7. Aug 8, 2017Phase 1 study in Healthy SubjectsNCT03245229 · 20 enrolled · Czechia
  8. May 17, 2018Phase 3 study in Resistant HypertensionNCT03541174 · 730 enrolled · United States, Australia, Belgium and more
  9. Jul 2, 2018Phase 1 study in Healthy SubjectsNCT03586570 · 20 enrolled · United States
  10. Nov 11, 2019Phase 3 study in HypertensionNCT04162366
  11. Jan 31, 2020Phase 1 study in Liver DiseasesNCT04252495 · 17 enrolled · Germany, Poland
  12. Feb 20, 2020Phase 1 study in Healthy SubjectsNCT04281342 · 48 enrolled · Germany
  13. Jan 5, 2022Phase 1 study in Healthy SubjectsNCT05196399 · 36 enrolled · Czechia
  14. Jan 14, 2025Phase 1 study in Drug Drug InteractionNCT06799884 · 19 enrolled · Czechia

TargetBeta

EDNRA →EDNRB →read by rule
“Endothelin receptor, ET-A/ET-B antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
BosentanruleJohnson & Johnsonphase 437

Studies

All 13 Idorsia Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06799884Drug Drug Interaction · Czechia1CompletedFeb 21, 202519
NCT05196399Healthy Subjects · Czechia1CompletedMar 27, 202236
NCT04281342Healthy Subjects · Germany1CompletedAug 3, 202148
NCT04252495Liver Diseases · Germany, Poland1CompletedApr 5, 202117
NCT04162366Hypertension3WithdrawnJun 30, 20210
NCT03586570Healthy Subjects · United States1CompletedSep 10, 201820
NCT03541174Resistant Hypertension · United States, Australia, Belgium and more3CompletedMay 14, 2021730
NCT03245229Healthy Subjects · Czechia1CompletedSep 18, 201720
NCT03165071Renal Insufficiency · Czechia1CompletedOct 27, 201716
NCT03100591Healthy Subjects · Netherlands1CompletedApr 18, 20176
NCT02841761Healthy Subjects · United States1CompletedSep 1, 201620
NCT02708004Healthy Subjects · Switzerland1CompletedDec 1, 201624
NCT02603809Essential Hypertension · United States, Canada, Israel and more2CompletedFeb 28, 20171,659

How it is read

Names in the registry

  • “Aprocitentan”, 5 entries
  • “Aprocitentan 25 mg”, 4 entries
  • “Aprocitentan tablets(SYH9108)”, 1 entry
  • “Aprocitentan 12.5 mg”, 1 entry
  • “14C-radiolabeled ACT-132577”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.